RxDoctor Payments DataLook up a doctor →

Matthew Aman

Gerontology · Rochester Hills, MINPI 1366094435

Payments from drug & device makers

$21,469in general payments, 2019–2025

Across 1,031 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • Johnson & Johnson$4K
  • UCB, Inc.$2K
  • AbbVie$2K
  • Novartis$1K
  • Pfizer$1K
  • plus $5K from 21 others

What the payments were for

  • Consulting fees$1,7408%
  • Food & beverage$19,41590%
  • Education$3141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,469 in reported general payments places this provider in the 95th percentile of 279 gerontology providers in Michigan.

See all gerontology providers in Michigan

Medicare billing

Part B allowed, 2024
$78,918
Medicare patients
289
Services billed
2,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib87$554,083
Humira(Cf) PenAdalimumab59$523,854
Enbrel SureclickEtanercept60$433,581
EnbrelEtanercept44$335,645
OtezlaApremilast66$316,958
Enbrel MiniEtanercept36$265,353
Xeljanz XrTofacitinib Citrate37$245,151
TremfyaGuselkumab16$212,646
Cosentyx Unoready PenSecukinumab27$197,562
Humira PenAdalimumab19$171,891
Cimzia (2 Pack)Certolizumab Pegol26$144,793
Orencia ClickjectAbatacept21$122,537
SimponiGolimumab13$81,100
OrenciaAbatacept12$75,180
HumiraAdalimumab11$73,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$5,431$652,603110 claims
AbbVieRinvoq, Humira$2,296$627,44298 claims
Johnson & JohnsonTremfya, Simponi$4,454$293,74629 claims
UCB, Inc.Cimzia (2 Pack)$2,492$144,79326 claims
E.r. Squibb & Sons, L.L.C.Orencia$918$75,18012 claims
Lilly USA, LLCForteo$359$45,42311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 279 gerontology providers in Michigan.

Other gerontology in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →